New data from the Diabetes Prevention Outcomes Study shows persistent reduction of type 2 diabetes development over 22-year average follow-up.
Long-term follow-up of participants enrolled in the Diabetes Prevention Program Outcomes Study (DPPOS) demonstrates a significant and persistent reduction in risk for type 2 diabetes. The latest DPPOS results were presented at the American Diabetes Association 80th Virtual Scientific Sessions. The DPP/DPPOS is the largest and longest running diabetes prevention study that continues to actively follow participants.
In the short slide show below, find highlights from the symposium, “New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS).”
DPPOS at 22 --At 22 years, data demonstrate persistent reduction in development of type 2 diabetes.
Diabetes Prevention Program Outcome Study (DPPOS) - long-term follow-up of the original Diabetes Prevention Program multicenter trial conducted from 1996-2001.
DPP treatment groups -- intensive lifestyle intervention that targeted weight loss and metformin group. Risk of T2D reduced by 58% and 31%, respectively, vs placebo at 3 years.
Large % of original DPP cohort continues in DPPOS -- What are the long-term effects of DPP interventions on further development of T2D & complications, ie, retinopathy, nephropathy, cardiovascular disease (CVD)?
The long-term view -- Today: After an average of 22 yrs of study, 75% of living original DPP participants continue to be evaluated. What will be the impact of long-term metformin treatment on major CVD?
DPP prevention effects durable a 22 years - Prevention effects in the original lifestyle group and metformin treatment group remain 22 yrsafter the start of the study with a 25%and 18% reduced risk of diabetes development, respectively, compared with the original placebo group.
Lower risk of micro- and macrovascular disease -- those who did not develop diabetes had signifcant 57% lower risk of developing early changes of eye disease and 37% lower risk for early signs of kidney disease and a 39% lower risk of major CVD endpoints.
Little benefit overall of individual interventions -- Despite the benefits seen with diabetes prevention overall, no significant benefit seen with individual interventions—metformin or lifestyle intervention—on heart disease or development of kidney disease or diabetic retinopathy. But: favorable trends are seen with metformin in stroke reduction and for CV events in the subgroup of people who started the study before age 45 yrs.
Intensive lifestyle intervention associated with lower risk of cancer and with long-term reduction in the development of frailty.
Negligible long-term negative effects -- The only long-term negative effect observed with any of the interventions was a modest increase in kidney disease with metformin, which appeared only in the oldest group of participants.
"The long-term benefits of the two DPP interventionson diabetes development, still present many years afterthey were started, are a testament to the power of these interventions and reinforce their importance in the reduction of diabetes."
David M.Nathan, MD, DPPOS chair, director of the Clinical Research Center and Diabetes Center at Massachusetts General Hospital and professor of medicine at Harvard Medical School. (ADA press release)
